ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 1 of 41
JMBS 2017, 2(1): 7–11
Experimental Medicine

The Influence of Alkilselenonaftiridin on Levels in Blood of Lipoproteins High, Low and Very Low Density on a Background of Experimental Diabetes

Awad Ali Riyadh

Correction of disturbances in lipid metabolism by diabetes remains a problem today. The aim of this work was to study the impact alkilselenonaftiridin (ASNR) on the dynamics of changes in the blood serum of levels lipoproteins of high (HDL), low (LDL) and very low (VLDL) density on the background of experimental streptozotocin-induced diabetes (DM). ASNR (180 mg / 100 g) were administered daily from the first day and 21ht day experiment in two different groups. It is shown that diabetes leads to changes in the lipid composition of blood - reducing the level of HDL and, conversely, increased LDL and VLDL levels. Introduction ASNR positively influenced the change of levels these of lipoproteins. Especially in the case when ASNR administered on the first day of the experiment. In particular, the introduction ASNR the first day of the experiment prevents significant reduction of HDL levels, such as 8.3 and 9.9% on the 20th and 40th day of the experiment, respectively. ASNR prevents increasing of LDL levels on 13.3 and 10.4% on the 20th and 40th days experiment, respectively. Simultaneously, ASNR reduces the negative impact of DM on VLDL levels on 7.4, 11.1 and 21.4 % on the 20th, 40th and 60th day experiment in accordance. However, the introduction of ASNR with 21st day of the experiment has little effect on changes of levels lipoproteins, caused by the development of DM. Except reduction on 13.3 % the negative impact of diabetes on levels of VLDL on the 60th day of the experiment. Thus, the introduction of ASNR positively influenced the change of levels lipoproteins of high, low and very low density on the background of experimental streptozotocin-induced diabetes.

Keywords: experimental diabetes, lipoproteins, alkilselenonaftiridin

Full text: PDF (Eng) 186K

  1. Balabolkin MI. Diabetology. Moscow, Medicine; 2000. 672 p.
  2. Shaw JE, Shaw RA, Zimmet Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87: 4-14.
  3. International Diabetes Federation. Diabetes Atlas Second Edition. 2003; 17-71.
  4. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, Engelgau MM, Vinicor F. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care. 2004; 27 (12): 2806 - 12.
  5. Sekikawa A, Eguchi H, Tominaga M, Igarashi K, Abe T, Manaka H, Sasaki H, Fukuyama H, Kato T, Kiyohara Y, Fujishima M. Prevalence of type 2 diabetes mellitus and impaired glucose tollerantce in a rural area of Japan. The Funagata diabetes study. J Diabetes Complications. 2000 Mar-Apr; 14 (2): 78-83.
  6. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002 May; 25 (5): 829-34.
  7. Mayakov AI, Beacons AI, Intercession TG, Pokrovsky MV. Endothelial dysfunction in the background fructose indutsirovannoy models of metabolic disorders in rats. XVII Russian National Congress "Man and medicine" 2010; 676-7.
  8. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. Vascular complications of diabetes. BMJ. 2000 Apr 15; 320 (7241): 1062-6.
  9. Zapadnyuk IP, Zacharias AE. Laboratory animals. Breeding, maintenance, use in the experiment. 3rd. Kyiv: Vyscha shkola; 1983. s. 243-76.
  10. Polyakov LE. Statistical methods for research in medicine and health. Leningrad: Medicine; 1971. 200 p.
  11. European convention for the protection of vertebral animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. Strasbourg, 1986; European Treaty Series.123.
  12. Ansari MA, Ahmad AS, Ahmad M. Selenium protects cerebral ischemia in rat brain mitochondria. Biol Trace Elem Res. 2004; 101 (1): 73-86.
  13. Stanishovski NV. Effect of ischemic appear on morph functional adaptation to cardiac myocardial necrosis at introduction Alkil Selenonaftiridin (experimental research). Kharkov, 2008.
  14. Panfilova V, Taranushenko TE, Salmin AB, et al. High-density lipoprotein as an indicator of vascular dysfunction in children with type 1 diabetes. Saratov Journal of Medical Science. 2011; 7 (4): 973- 5.
  15. Bozhko G, Pertseva T, Chursina V, Sokolik V. Features dislipoproteinemia in patients with encephalopathy distsirkulyatornoy diabetes mellitus type II Ukrainian Journal Neuropsychiatries. 2004; 12 (1): 107-9.